Spectrum is committed to helping your patients access KHAPZORY
For patients with commercial healthcare insurance
The Spectrum Therapy Access Resources (STAR®) co-pay program is designed to assist patients who meet the eligibility criteria with certain co-pay, co-insurance, or deductible expenses (cost share) related to a Spectrum product.*
- First Date of Service: $0 patient out of pocket. STAR will cover 100% of the co-insurance/cost share for the Spectrum product.
- Subsequent Dates of Service: Patient will be responsible for the first $25 of the co-insurance/cost share for the Spectrum product. STAR will cover the remaining cost share for the Spectrum product at 100%.
Or contact 1-888-53-STAR7 or 1-888-537-8277
*This program provides up to $10,000 per calendar year to assist with patient co-pay/co-insurance costs. The patient is responsible for any out of pocket costs above this amount.
Spectrum Pharmaceuticals, Inc.® does not guarantee coverage and/or reimbursement for its products. Coverage, coding, and reimbursement polices vary significantly by payer, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. Health care professionals should always verify coverage, coding, and reimbursement guidelines on a payer-and patient-specific basis. Spectrum Pharmaceuticals, Inc. reserves the right to change eligibility guidelines, or terminate, or modify the STAR program at any time for any reason.
Indications and Usage
KHAPZORYTM is a folate analog indicated for:
- Rescue after high-dose methotrexate therapy in patients with osteosarcoma.
- Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination.
- Treatment of patients with metastatic colorectal cancer in combination with fluorouracil.
Limitations of Use
KHAPZORY is not indicated for the treatment of pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12 because of the risk of progression of neurologic manifestations despite hematologic remission.
Important Safety Information
- KHAPZORY is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid, or folinic acid.
Warnings and Precautions
- Increased gastrointestinal toxicities with fluorouracil: Gastrointestinal toxicities, including stomatitis and diarrhea, occur more commonly and may be of greater severity and of prolonged duration. Deaths from severe enterocolitis, diarrhea, and dehydration have occurred in elderly patients receiving weekly d,l-leucovorin and fluorouracil. Do not initiate or continue therapy with KHAPZORY and fluorouracil in patients with symptoms of gastrointestinal toxicity until those symptoms have resolved. Monitor patients with diarrhea until it has resolved as rapid deterioration leading to death can occur.
- Drug interaction with trimethoprim-sulfamethoxazole: Concomitant use of d,l-leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis jiroveci pneumonia in patients with HIV infection increased treatment failure and morbidity.
- The most common adverse reactions (≥20%) in patients receiving high-dose methotrexate therapy with levoleucovorin rescue were stomatitis (38%) and vomiting (38%).
- The most common adverse reactions (>50%) in patients receiving levoleucovorin in combination with fluorouracil for metastatic colorectal cancer were stomatitis (72%), diarrhea (70%), and nausea (62%).
Leucovorin products increase the toxicity of fluorouracil.
Use in Specific Populations
Levoleucovorin is administered in combination with methotrexate or fluorouracil, which can cause embryo-fetal harm. Refer to methotrexate and fluorouracil prescribing information for additional information.
Please click here to see full Prescribing Information for KHAPZORY.
Reporting of Suspected Adverse Reactions
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.